Proton Pump Inhibitor for Gastrointestinal Bleeding in Patients with Myocardial Infarction on Dual-Antiplatelet Therapy: A Nationwide Cohort Study
Open Access
- 24 June 2024
- journal article
- research article
- Published by Springer Nature in Journal of Epidemiology and Global Health
- Vol. 14 (3) , 1142-1151
Abstract
Background: Guidelines provide various recommendations for the use of proton pump inhibitors (PPI) to prevent upper gastrointestinal (UGI) bleeding in acute myocardial infarction (MI) treatment with dual antiplatelet therapy (DAPT). We evaluated the effects of PPIs in reducing the risk of severe UGI bleeding in patients with MI receiving DAPT. Methods: This retrospective cohort study included patients admitted for acute MI between 2014 and 2018, based on a nationwide health claims database in Korea. Primary outcome was admission for severe UGI bleeding requiring transfusion within 1 year of MI diagnosis. A multivariable Cox regression model was used to calculate the association between PPI use and severe UGI bleeding risk. Results: Of 100,556 patients with MI on DAPT (mean age, 63.7 years; 75.4% men), 37% were prescribed PPIs. Based on risk assessment for UGI bleeding, among 6,392 (6.4%) high-risk and 94,164 (93.6%) low-risk patients, 50.5% and 35.8% received PPIs, respectively. Overall, 0.5% of the patients experienced severe UGI bleeding within 1 year after MI. The use of PPI was associated with a reduced risk of severe UGI bleeding (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.47–0.70; P < 0.001). The benefits of PPIs were consistent in high-risk (HR, 0.71; 95% CI, 0.45–1.13; P = 0.147) and low-risk (HR, 0.54; 95% CI, 0.43–0.68; P < 0.001) patients (P for interaction = 0.481). Conclusions: Among Korean patients with MI receiving DAPT, PPIs were underutilized, even among those at high risk of severe UGI bleeding. Nonetheless, PPI use reduced severe UGI bleeding in low- and high-risk groups.Keywords
Funding Information
- Yonsei University College of Medicine (6-2022-0047)
- Ministry of Education (NRF-2021R1I1A1A0104944111)
This publication has 28 references indexed in Scilit:
- 2023 ESC Guidelines for the management of acute coronary syndromesEuropean Heart Journal, 2023
- AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert ReviewGastroenterology, 2022
- 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive SummaryJACC, 2022
- Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or AspirinGastroenterology, 2019
- Ideal Blood Pressure in Patients With Atrial FibrillationJACC, 2018
- Proton Pump Inhibitors Are Underprescribed in Patients Discharged on Dual Antiplatelet Therapy After Acute Coronary SyndromeGastroenterology, 2018
- No Significant Association Between Proton Pump Inhibitor Use and Risk of Stroke After Adjustment for Lifestyle Factors and IndicationGastroenterology, 2018
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSEuropean Heart Journal, 2017
- The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological AssociationGastroenterology, 2017
- Clopidogrel with or without Omeprazole in Coronary Artery DiseaseNew England Journal of Medicine, 2010